Synthesis, biological activity evaluation and mechanism of action of novel bis-isatin derivatives as potential anti-liver cancer agents
作者:Zhifen Li、Jingbo Ma、Ming Tian、Peng Xia、Xiannian Lv、Rui Hou、Yuke Jiang、Xiaolong Xu、Zhifang Jia、Jigang Wang、Zhijie Li
DOI:10.1016/j.bmcl.2024.129613
日期:2024.2
derivatives (0–100 μM) were first screened against liver cancer cell lines(Huh1, H22, Huh7, Hepa1-6, HepG2, Huh6 and 97H) using CCK-8 assay. Results indicated that the derivative exhibited the most potent activity against Huh1 (IC = 17.13 µM) and Huh7(IC = 8.265 µM). anti-tumor study showed that compound effectively inhibited tumor growth in Huh1-induced xenograft mouse model; the anti-tumor effect of compound
合成了一系列带有赖氨酸接头的双靛红缀合物,旨在探讨其抗增殖潜力。所有新合成的衍生物(0-100 μM)首先使用 CCK-8 测定针对肝癌细胞系(Huh1、H22、Huh7、Hepa1-6、HepG2、Huh6 和 97H)进行筛选。结果表明,该衍生物对 Huh1 (IC = 17.13 µM) 和 Huh7 (IC = 8.265 µM) 表现出最有效的活性。抗肿瘤研究表明,该化合物能有效抑制Huh1诱导的异种移植小鼠模型中的肿瘤生长;化合物(15mg/kg)的抗肿瘤作用与索拉非尼(20mg/kg)相当。进行H&E染色分析、常规血检和血清生化检查以确认化合物在异种移植模型中的安全性。通过RNA-Seq分析进一步研究了其抑制肿瘤生长的作用机制,表明自噬信号通路的正向调节,并通过治疗后自噬关键生物标志物的表达进一步证实。我们的结果表明,双靛红缀合物是治疗某些肝癌的一种有前途的肿瘤抑制剂。